BeiGene 대차 대조표 상태

재무 상태 기준 확인 4/6

BeiGene 의 총 주주 지분은 CN¥24.2B 이고 총 부채는 CN¥7.2B, 이는 부채 대 자기자본 비율을 29.6% 로 가져옵니다. 총자산과 총부채는 각각 CN¥40.9B 및 CN¥16.7B 입니다.

주요 정보

29.6%

부채 비율

CN¥7.16b

부채

이자 보상 비율	n/a
현금	CN¥19.04b
주식	CN¥24.17b
총 부채	CN¥16.68b
총 자산	CN¥40.86b

최근 재무 상태 업데이트

Recent updates

BeiGene: TEVIMBRA European Push Continues With Positive CHMP Opinion

Nov 06

BeiGene: Poised For Re-Rating As BTKi Sales Show Strong Beat

Aug 22

Analysts Just Made An Incredible Upgrade To Their BeiGene, Ltd. (NASDAQ:BGNE) Forecasts

Aug 14

BeiGene, Ltd. (NASDAQ:BGNE) Shares Fly 27% But Investors Aren't Buying For Growth

Aug 09

BeiGene: Navigating Patent Disputes Towards Profitability (Rating Upgrade)

Jun 21

We Think Some Shareholders May Hesitate To Increase BeiGene, Ltd.'s (NASDAQ:BGNE) CEO Compensation

May 30

Is BeiGene (NASDAQ:BGNE) Using Too Much Debt?

Apr 21

BeiGene Still Bleeding Red Ink Despite Blockbuster Drug

Mar 08

BeiGene, Ltd.'s (NASDAQ:BGNE) Intrinsic Value Is Potentially 26% Above Its Share Price

Jan 31

Here's Why BeiGene (NASDAQ:BGNE) Can Manage Its Debt Despite Losing Money

Oct 16

Is There An Opportunity With BeiGene, Ltd.'s (NASDAQ:BGNE) 39% Undervaluation?

Jul 11

Rock star Growth Puts BeiGene (NASDAQ:BGNE) In A Position To Use Debt

Jun 19

Revenues Not Telling The Story For BeiGene, Ltd. (NASDAQ:BGNE)

Apr 17

A Look At The Fair Value Of BeiGene, Ltd. (NASDAQ:BGNE)

Mar 24

재무 상태 분석

단기부채: BGNE 의 단기 자산 ( CN¥27.4B )이 단기 부채( CN¥14.2B ).

장기 부채: BGNE 의 단기 자산( CN¥27.4B )이 장기 부채( CN¥2.5B ).

부채 대 자본 내역 및 분석

부채 수준: BGNE 총 부채보다 더 많은 현금을 보유하고 있습니다.

부채 감소: BGNE 의 부채 대 자기자본 비율은 지난 5년간 19.8% 에서 29.6% 로 증가했습니다.

대차 대조표

현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: BGNE 현재 무료 현금 흐름을 기준으로 1년 이상 충분한 현금 활주로를 보유하고 있습니다.

예측 현금 활주로: BGNE 의 여유 현금 흐름이 역사적 비율에 따라 계속 증가하거나 감소하는 경우 충분한 현금 활주로가 있는지 판단하기에는 데이터가 부족합니다.

BeiGene 대차 대조표 상태

재무 상태 기준 확인 4/6

주요 정보

최근 재무 상태 업데이트

Is BeiGene (NASDAQ:BGNE) Using Too Much Debt?

Here's Why BeiGene (NASDAQ:BGNE) Can Manage Its Debt Despite Losing Money

Rock star Growth Puts BeiGene (NASDAQ:BGNE) In A Position To Use Debt

Recent updates

No longer forecast to breakeven

New major risk - Revenue and earnings growth

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

BeiGene: TEVIMBRA European Push Continues With Positive CHMP Opinion

New minor risk - Shareholder dilution

BeiGene, Ltd. Announces Passing Away of Donald Glazer, A Board Member and the Chair of the Nominating and Corporate Governance Committee

Co-Founder notifies of intention to sell stock

BeiGene, Ltd. to Report Q3, 2024 Results on Nov 13, 2024

Global Head of R&D notifies of intention to sell stock

BeiGene, Ltd. Appoints Shalini Sharp to Board of Directors and Member of the Audit Committee, Effective September 27, 2024

President & COO notifies of intention to sell stock

BeiGene Receives Israeli Ministry of Health Approval for TEVIMBRA® for the Treatment of Oesophageal Squamous Cell Carcinoma (OSCC) After Prior Chemotherapy

President & COO notifies of intention to sell stock

BeiGene: Poised For Re-Rating As BTKi Sales Show Strong Beat

Analysts Just Made An Incredible Upgrade To Their BeiGene, Ltd. (NASDAQ:BGNE) Forecasts

Consensus estimates of losses per share improve by 31%

BeiGene, Ltd. (NASDAQ:BGNE) Shares Fly 27% But Investors Aren't Buying For Growth

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

BeiGene, Ltd. to Report Q2, 2024 Results on Aug 07, 2024

Beigene, Ltd. Appoints Aaron Rosenberg as the Principal Financial Officer, Effective from July 22, 2024

BeiGene, Ltd. Announces CFO Changes

BeiGene, Ltd. to Report First Half, 2024 Results on Aug 30, 2024

BeiGene: Navigating Patent Disputes Towards Profitability (Rating Upgrade)

BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024

We Think Some Shareholders May Hesitate To Increase BeiGene, Ltd.'s (NASDAQ:BGNE) CEO Compensation

BeiGene, Ltd. Announces New Analyses for BRUKINSA® (zanubrutinib) At ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL

BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024

First quarter 2024 earnings released: US$2.41 loss per share (vs US$3.35 loss in 1Q 2023)

BeiGene, Ltd. Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer

Is BeiGene (NASDAQ:BGNE) Using Too Much Debt?

BeiGene, Ltd., Annual General Meeting, Jun 05, 2024

Co-Founder recently sold US$7.5m worth of stock

Co-Founder notifies of intention to sell stock

BeiGene, Ltd. to Report Q1, 2024 Results on May 11, 2024

BeiGene, Ltd. Receives FDA Approval for TEVIMBRA for Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy

Co-Founder notifies of intention to sell stock

BeiGene Still Bleeding Red Ink Despite Blockbuster Drug

BeiGene, Ltd. Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma

BeiGene, Ltd. to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024

BeiGene, Ltd. Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer

Full year 2023 earnings released: US$8.45 loss per share (vs US$19.43 loss in FY 2022)

BeiGene, Ltd. Announces Adults Living with Chronic Lymphocytic Leukemia in Ontario and Quebec Now Have Access, Through Public Reimbursement, to BRUKINSA® (Zanubrutinib)

BeiGene, Ltd.'s (NASDAQ:BGNE) Intrinsic Value Is Potentially 26% Above Its Share Price

Now 21% undervalued after recent price drop

Beigene, Ltd. Announces Board Changes

Now 22% undervalued after recent price drop

Forecast to breakeven in 2026

BeiGene, Ltd. Announces FDA Approves Label Update for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia

BeiGene, Ltd. Receives European Commission Approval for BRUKINSA®? (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma

Co-Founder notifies of intention to sell stock

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 11%

Consensus EPS estimates upgraded to US$11.07 loss

Beigene, Ltd. Receives Positive Recommendation from Nice in U.K. for Adult Patients with Chronic Lymphocytic Leukemia

BeiGene, Ltd. Presentations at ESMO 2023 Demonstrate Robust Clinical Strategy for Tislelizumab as Monotherapy and in Combination with Pipeli

Here's Why BeiGene (NASDAQ:BGNE) Can Manage Its Debt Despite Losing Money

BeiGene Receives Positive CHMP Opinion for BRUKINSA®? (zanubrutinib) in Relapsed or Refractory Follicular Lymphoma

Consensus EPS estimates fall by 18%

BeiGene Receives Positive CHMP Opinion for BRUKINSA®? (zanubrutinib) in Relapsed or Refractory Follicular Lymphoma

U.S. FDA Accepts Biologics License Application in First-Line Advanced ESCC

BeiGene, Ltd. Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA(R)

Beigene, Ltd. Announces Change of Chair of Audit Committee

New minor risk - Profitability

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

Second quarter 2023 earnings released: US$3.64 loss per share (vs US$5.51 loss in 2Q 2022)

Beigene Announces Positive CHMP Opinion for Tislelizumab as Treatment for Advanced or Metastatic ESCC

Beigene, Ltd. Announces FDA Acceptance of sNDA for Fifth Brukinsa(R) Indication

Is There An Opportunity With BeiGene, Ltd.'s (NASDAQ:BGNE) 39% Undervaluation?

BeiGene, Ltd. to Report First Half, 2023 Results on Aug 30, 2023